Anlotinib with Camrelizumab in Lung Cancer Treatment

Anlotinib with Camrelizumab in Lung Cancer Treatment Background Checkpoint inhibitors (CPIs) and anti-angiogenic agents are emerging as potential novel treatment choices for advanced cancers including metastatic non-small-cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatment of patients with advanced NSCLC.

Diffuse-Type Tenosynovial Giant Cell Tumors: Treatments and Progression

Diffuse-Type Tenosynovial Giant Cell Tumors: Treatments and Progression Tenosynovial giant cell tumors (TGCT) - An Introduction Tenosynovial giant cell tumors (TGCT) are rare, locally invasive lesions of synovial origin that involve joints, tendon sheaths, and bursae.  TGCT may be intra- or extra-articular and is classified by growth pattern and clinical presentation as

Renal Cell Carcinoma- Prognosis via Albumin Levels

Renal Cell Carcinoma- Prognosis via Albumin Levels Metastatic renal cell carcinoma (mRCC) - An Introduction Renal cell carcinoma (RCC) constitutes approximately 90% of all urologic malignancies. Approximately 30% of patients with RCC present with metastatic disease, and amongst those with localized disease, a substantial proportion will recur. Before 2005, immunotherapy with interleukin-2

Hodgkin’s Lymphoma: A Case Study with Nystagmus and Diplopia

Hodgkin's Lymphoma: A Case Study with Nystagmus and Diplopia INTRODUCTION Paraneoplastic neurologic syndromes (PNS) are uncommon but important clinical situations caused by cancer, but not a direct result of tumor invasion. As compared to solid tumors, the chances of association of PNS with lymphomas are quite low. However, Hodgkin's and non-Hodgkin's lymphomas,

Spence Children’s Anxiety Scale Validation

Validation of Spence Children's Anxiety Scale ANXIETY IN CHILDREN In Europe, anxiety disorders are highly prevalent and impairing conditions among children and adolescents. Up to 18 - 20% of youth in the general population presenting to primary care clinics report some internalizing problem. Previous studies showed that anxiety disorders start at an early

Koolen-de Vries Case Study

Koolen-de Vries syndrome in a 63-year-old woman: a review of the adult phenotype Koolen-de Vries syndrome (KdVS): An Introduction Also known as the 17q21.31 microdeletion syndrome, Koolen-de Vries syndrome (KdVS) was first described in 2006 in individuals with intellectual disabilities and organ abnormalities. KdVS was initially described in association with recurrent microdeletion

Anxiety Scales in Lewy Body Disease

Anxiety Scales in Lewy Body Disease Background Anxiety disorders and symptoms are frequent in Lewy Body Disease (LBD) and many scales are available to assess its severity.  Yet, there is little consensus on which scale best evaluates anxiety across LBD patients. Objective Comparing the convergent validity of commonly used anxiety scales across synuclein-based diseases. Lewy

Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT

Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT Inoperable locally advanced non-small cell lung cancer (NSCLC): An Introduction Accounting for approximately 80% of lung cancers, non-small cell lung cancer (NSCLC) is the most common subtype. Most NSCLC patients are diagnosed at an advanced stage with a mere 15-20%

Physician Spending And Its Association With Patient Outcomes

Physician Spending And Its Association With Patient Outcomes Global spending on health is soaring at a rapid rate. The total health expenditure (THE) worldwide increased from US$ 7.6 trillion in 2016 to US$ 7.8 trillion in 2017. The World Health Organization 2020 report stated that it reached US$ 8.3 trillion or

Physician Burnout: Causes and Prevention

Physician Burnout: Causes and Prevention The data is indisputable: Physicians across the globe are emotionally drained and overworked due to increasing demands on the profession. Numerous global studies indicate that one in every three physicians experiences burnout at any given time. Originally used by Herbert Freudenberger in 1974 and subsequently described by

Anlotinib with Camrelizumab in Lung Cancer Treatment